HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

New Entrants in Gadobutrol Market Heighten Competitive Dynamics

Intelligence briefing

Intelligence Briefing · ~4 min read

New Entrants in Gadobutrol Market Heighten Competitive Dynamics

Imaging · Contrast Agent

Type

Strategic Briefing

Generated

Jul 23, 2026

Confidence

Moderate Confidence · 72%

Evidence

10 items

Sources

10

Key Takeaways

Leadership-ready summary — read in 4 minutes.

  • Zenara's entry with Gadobutrol may impact pricing and market share dynamics among existing contrast agents. The strongest clinical anchor is Opportunistic Breast Cancer Screening Using Non-Contrast Chest CT (ClinicalTrials.gov), moderate corpus alignment. In Imaging · Contrast Agent, 5 regulatory and 3 competitive items passed relevance filtering for Zenara.
  • Monitor the market uptake of Gadobutrol from Zenara and Viwit Pharm, particularly initial sales performance and physician adoption rates.
  • Watch for competitive responses from established players, including potential pricing adjustments or new product launches.

Why It Matters

Strategic context for leadership and portfolio decision-making.

Zenara's entry with Gadobutrol may impact pricing and market share dynamics among existing contrast agents. The strongest clinical anchor is Opportunistic Breast Cancer Screening Using Non-Contrast Chest CT (ClinicalTrials.gov), moderate corpus alignment. In Imaging · Contrast Agent, 5 regulatory and 3 competitive items passed relevance filtering for Zenara.

Supporting Evidence

Evidence-backed items from the Humanexa intelligence graph.

  • FDA Grants Approval for Gadobutrol ANDA219146 by Zenara

    Imaging · Contrast Agent

    Source: Regulatory Approval

    View evidence
  • FDA Grants Approval for Gadobutrol ANDA219287 by Viwit Pharm

    Imaging · Contrast Agent

    Source: Regulatory Approval

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • FDA Grants Approval for Gadobutrol ANDA219146 by Zenara

    Imaging · Contrast Agent

  • FDA Grants Approval for Gadobutrol ANDA219287 by Viwit Pharm

    Imaging · Contrast Agent

Insights

  • New Entrants in Gadobutrol Market Heighten Competitive Dynamics

    Imaging · Contrast Agent

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.